NASDAQ:DMAC - DiaMedica Therapeutics Stock Price, Forecast & News

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

DiaMedica Therapeutics Inc (NASDAQ:DMAC) issued its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.01. View DiaMedica Therapeutics' Earnings History.

DiaMedica Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for DiaMedica Therapeutics.

3 analysts have issued twelve-month target prices for DiaMedica Therapeutics' stock. Their forecasts range from $8.00 to $11.00. On average, they expect DiaMedica Therapeutics' stock price to reach $9.33 in the next year. This suggests a possible upside of 65.5% from the stock's current price. View Analyst Price Targets for DiaMedica Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DiaMedica Therapeutics.

Headlines about DMAC stock have been trending somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. DiaMedica Therapeutics earned a news sentiment score of 1.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for DiaMedica Therapeutics.

DiaMedica Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 15,700 shares, a drop of 56.6% from the January 15th total of 36,200 shares. Based on an average daily trading volume, of 44,500 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.2% of the company's shares are sold short. View DiaMedica Therapeutics' Current Options Chain.

Some companies that are related to DiaMedica Therapeutics include VBI Vaccines (VBIV), Seres Therapeutics (MCRB), Avadel Pharmaceuticals (AVDL), Advanz Pharma (CXRXF), Hookipa Pharma (HOOK), Ocular Therapeutix (OCUL), Geron (GERN), IVERIC bio (ISEE), MEI Pharma (MEIP), BIOFRONTERA AG/ADR (BFRA), Kalvista Pharmaceuticals (KALV), XOMA (XOMA), Protagonist Therapeutics (PTGX), Sol Gel Technologies (SLGL) and Kala Pharmaceuticals (KALA).

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include Inovio Pharmaceuticals (INO), vTv Therapeutics (VTVT), Agile Therapeutics (AGRX), Nabriva Therapeutics (NBRV), Oncolytics Biotech (ONCY), Seelos Therapeutics (SEEL), VBI Vaccines (VBIV), Achieve Life Sciences (ACHV), Adamis Pharmaceuticals (ADMP) and Adamas Pharmaceuticals (ADMS).

(DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

DiaMedica Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.15%) and Blair William & Co. IL (0.08%). Company insiders that own DiaMedica Therapeutics stock include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen. View Institutional Ownership Trends for DiaMedica Therapeutics.

DMAC stock was acquired by a variety of institutional investors in the last quarter, including Blair William & Co. IL and Geode Capital Management LLC. Company insiders that have bought DiaMedica Therapeutics stock in the last two years include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen. View Insider Buying and Selling for DiaMedica Therapeutics.

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DMAC stock can currently be purchased for approximately $5.64.

DiaMedica Therapeutics has a market capitalization of $67.45 million and generates $500,000.00 in revenue each year. DiaMedica Therapeutics employs 9 workers across the globe.View Additional Information About DiaMedica Therapeutics.

The official website for DiaMedica Therapeutics is http://www.diamedica.com/.

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]